Ginkgo Bioworks Holdings Return on Tangible Equity 2020-2022 | DNA
Current and historical return on tangible equity values for Ginkgo Bioworks Holdings (DNA) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Ginkgo Bioworks Holdings Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2022-12-31 |
$-2.11B |
$1.57B |
-140.47% |
| 2022-09-30 |
$-3.53B |
$1.36B |
-237.07% |
| 2022-06-30 |
$-2.96B |
$1.50B |
-192.03% |
| 2022-03-31 |
$-2.35B |
$1.57B |
-200.68% |
| 2021-12-31 |
$-1.83B |
$1.52B |
-235.27% |
| 2021-06-30 |
$-0.15B |
$0.01B |
-6160.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.549B |
$0.478B |
|
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
|
